NZ part of testing of HydroChloroquine trials

The three trials are being led by the Medical Research Institute with almost $1 million of funding from the state-run Health Research Council of New Zealand.

The first trial will test 16 drugs, including hydroxychloroquine, azithromycin and steroids, on thousands of patients in intensive care with Covid-19-related pneumonia, across 15 countries.

Trial co-leader, Auckland City Hospital Intensive Care specialist Dr Colin McArthur, said because of this country's involvement, New Zealand patients will receive treatment that is likely to be more effective.

"It allows us to evaluate several treatments at the same time, in the same patient, combining the results from around the world, then use this to influence care for future patients, to ensure they too are more likely to receive the best treatment regime available.

"We can quickly drop treatments if they are shown to be less effective than others or worse than standard care, and add others to the study over time if need be," Dr MrArthur said.

In the second trial, the anti-malaria drug hydroxychloroquine - hailed prematurely as a cure by the US president Donald Trump - will be given to 70 people with the virus in Wellington and Auckland who do not require hospital treatment.

The volunteer patients will be required to document their symptoms for 28 days.

https://www.rnz.co.nz/news/national/414479/kiwi-researchers-lead-clinical-drug-trials-to-tackle-covid-19